Skip to content

Follow-up After Surgery for Colon Cancer. General Practice vs. Surgical-based Follow-up?

Should the Surgeon or the General Practitioner (GP) Follow up Patients After Surgery for Colon Cancer? A Randomized Controlled Trial Focusing on Quality of Life, Cost-effectiveness and Serious Clinical Events.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00572143
Acronym
ONKOLINK
Enrollment
180
Registered
2007-12-12
Start date
2007-06-30
Completion date
2013-06-30
Last updated
2016-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Keywords

Colonic Neoplasms/surgery*, Continuity of Patient Care*, Follow-Up Studies, Quality of Life, Patient Satisfaction

Brief summary

The purpose of this study is to clarify cost effectiveness and quality of life issues among colon cancer patients followed up in a hospital setting or by their GP's.Statement of study hypothesis:Postoperative follow up of colon cancer patients (according to national guidelines) by general practitioners will not have any influence on patients' quality of life. There will not be observed any increase in serious clinical events and cost effectiveness will be improved.

Interventions

OTHERca coli follow-up by GP

patients randomized to follow up by GP

Sponsors

University Hospital of North Norway
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Surgery for colon cancer (including rectosigmoid) with histological grade Duke stages A, B or C. * Completion of postsurgical chemotherapy (Dukes stage C patients). * Informed consent.

Exclusion criteria

* Patients with rectal cancer defined as cancer within 15 cm from anus. * A poor health status or operative complications making it natural to perform follow up by specialists. * Additional cancer diagnoses. * Disseminated cancer. * Poor mental status.

Design outcomes

Primary

MeasureTime frame
Quality of life; EORTC-QLQ-C30 and EQ 5D2 years

Secondary

MeasureTime frame
Cost-effectiveness Serious clinical events2 years

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026